Category Archives: Blogs

Welcome to FixHepC, a trusted resource for those seeking effective and affordable solutions for Hepatitis C treatment. Our mission is to empower individuals with the knowledge and access to life-saving medications, ensuring that everyone has the opportunity to cure this condition. With expert guidance, patient testimonials, and up-to-date information on the latest treatments, we are here to support your journey toward a Hepatitis C-free life. Explore our resources, learn more about your treatment options, and take the first step toward a healthier future.

Our blog at FixHepC is dedicated to providing valuable insights, updates, and support for those affected by Hepatitis C. Here, you’ll find a wide range of topics, including the latest breakthroughs in Hepatitis C treatments, expert tips on managing the condition, and personal stories from individuals who have successfully undergone treatment. We also cover important health news, information on accessing affordable medications, and advice on navigating the healthcare system. Whether you’re newly diagnosed or exploring treatment options, our blog offers clear, reliable, and compassionate information to help you make informed decisions about your health.

Sofosbuvir+Daclatasvir results shine – bad news for Epclusa and Maviret?

The combination of Sovaldi (Sofosbuvir) and Daklinza (Daclatasvir) was the world’s first pan-genotypic Hepatitis C treatment. In the USA and Europe the $140,000 price tag of this combination means it has seen relatively little use, but in the world of generics it has seen extensive use because Daclatasvir is much cheaper to produce than either […]

Pharmaniaga, Pharco and DNDi Sign Agreement to Provide Affordable Hepatitis C Treatment in Malaysia

Marty Two Bulls

KUALA LUMPUR/GENEVA – 13th November 2017 – Malaysian pharmaceutical company Pharmaniaga Logistics Sdn Bhd (Pharmaniaga), Egyptian pharmaceutical company Pharco Pharmaceuticals (Pharco) and non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration agreement to supply a new hepatitis C treatment regimen to be sold for US$300 in the public sector […]

We have the power to FixHepC, but the real question is…

Thanks to Marty2Bulls for the butterfly

We have the power to FixHepC, but the real question is… Do we have the willpower? This was how Dr James Freeman ended his presentation at the World Hepatitis Summit in Brazil. You can watch the full presentation on YouTube. In essence, if we applied the same effort to HCV as we do to HIV […]

Qualifying for Social Security Disability Benefits With Hepatitis C

Hepatitis C is a disease that can make you feel old before your time. While there is no doubt that treatment with the new generation of direct acting antivirals like Harvoni is by far the best option this is not available to everyone, either because they don’t qualify under their insurance, don’t have insurance, or […]

AASLD 2017: Generics shown to be bioequivalent to originator brands

Just out of embargo for AASLD 2017 is the rather innocuous sounding Abstract 1078 which says, in brief, that these generic DAAs are inarguably proven the same as the originator DAAs. Bioequivalent pharmacokinetics for generic and originator Hepatitis C Direct Acting Antivirals Andrew M. Hill1, Loai Tahat2, Mohammed Khalil Mohammed3, Sanjay Nath4, Rabab Fayez Tayyem3, James […]

Bye bye limitatio (and generics) – Open access to the new Hepatitis C medications for all Swiss patients

Switzerland has just announced that all limitations on access to the new DAAs will be abolished allowing treatment for all. Great news for Swiss patients. Here is an article from the Swiss Hepatitis C Association about it. If you are not lucky enough to live in Switzerland generic versions of the new medications are available […]

× Chat